At a glance
ClinicalIndex Comparison RecordN/ACompleted· 59 enrolled
Drug / intervention
Cefaly® Abortive Program devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Abortive Treatment of Migraine With the Cefaly® Abortive Program Device: Pilot Trial
In Brief
A clinical study evaluating Cefaly® Abortive Program device for Migraine. Completed, enrolled 59 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack. This open clinical trial will study the abortive treatment of migraine using the Cefaly® Abortive Program device, prior to development of a sham-controlled trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartAug 2017
Primary CompletionJan 2018
TodayJul 2026
First PostedJul 14, 2017
Enrollment StartAug 10, 2017
Primary CompletionJan 10, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.0 years ago
Interventions
Cefaly® Abortive Program devicedevice
The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS).